Inhibikase Therapeutics, Inc. announces the pricing of its public offering, including 46,091,739 shares of common stock and pre-funded warrants. The offering price is $1.45 per share for common stock and $1.449 per pre-funded warrant, with expected gross proceeds of approximately $100.0 million. The offering is expected to close on November 24, 2025, with Jefferies, BofA Securities, and Cantor as joint book-running managers. The securities are being offered under a shelf registration statement on Form S-3. Inhibikase is a clinical-stage pharmaceutical company developing therapeutics for cardiopulmonary diseases like Pulmonary Arterial Hypertension (PAH).

Read more at GlobeNewswire: Inhibikase Therapeutics Announces Pricing of $100 Million